FDA considers appetite-curbing implant for severely obese

June 17, 2014 by Dennis Thompson, Healthday Reporter
FDA considers appetite-curbing implant for severely obese
Agency committee weighs application of nerve-stimulating device.

(HealthDay)—A new implant designed to curb the appetite by electrically stimulating stomach nerves is under review Tuesday by a key advisory committee of the U.S. Food and Drug Administration.

The device is aimed at severely obese adults who have failed to slim down using traditional methods, but don't want, or can't have, weight-loss surgery, the manufacturer, EnteroMedics Inc., said in its application for FDA approval.

In the United States, more than one-third of adults are obese, according to the U.S. Centers for Disease Control and Prevention. This increases their risk of serious health issues such as heart disease, diabetes, depression and cancer, experts say.

Despite this, "we have very few tools at our disposal compared with other chronic diseases," said Martin Binks, an associate professor at Texas Tech University who will testify before the FDA panel on behalf of the Obesity Society.

"We certainly are encouraged by the FDA's recent willingness to review treatments for obesity, and we're hopeful the FDA will give a fair hearing and evaluate the device based on the merits," Binks said.

The Maestro Rechargeable System, as it's called, sends electrical signals to nerves around the stomach that help control digestion. These signals block the nerves, decreasing hunger pangs and making the person feel full, the St. Paul, Minn., manufacturer said.

In clinical trials, with a Maestro implant lost an average 8.5 percent more weight than others who received a fake implant, the device maker said.

"The Maestro Rechargeable System is a safe and effective treatment option for obese individuals who have failed more conservative weight reduction interventions such as diet/exercise and pharmacotherapy, but are not able or willing to undergo more aggressive bariatric surgical options," the device company said in FDA briefing papers.

The implant's safety and effectiveness will be evaluated by the gastroenterology and urology devices panel of the FDA's Medical Devices Advisory Committee.

The Maestro consists of a "pulse generator" surgically implanted under the skin of the chest wall. This delivers high-frequency electrical pulses to leads laid along two trunks of the vagus nerve, which helps control the function of many organs in the abdomen.

The device is intended in use for people with a body mass index (BMI) of at least 40, which is extremely obese. BMI is a measurement of body fat based on height and weight.

EnteroMedics said the Maestro also could be used in people with a BMI of at least 35 who have health problems related to their obesity and have failed to lose weight through other programs. (A BMI of 30 is the threshold for obesity.)

The FDA advisory committee's review will include results from a clinical trial that involved more than 200 morbidly (severely) obese people in the United States and Australia. Of those, 157 received a Maestro implant and 76 received a fake implant.

All of the participants then went through a standard weight management program, which consisted primarily of 15-minute counseling sessions. The program did not include more intense interventions such as very low calorie diets, mandatory exercise programs or portion-controlled meals.

Over the course of a year, study participants with the Maestro implant lost just over 24 percent of their on average, compared with nearly 16 percent of excess weight loss for people who received fake implants.

More than half the participants lost at least one-fifth of their excess weight, and 38 percent lost at least one-quarter of their excess weight, according to the researchers.

EnteroMedics added that people with fake implants regained about 40 percent of the weight they had lost within six months of the trial's end, while the people with the Maestro device appeared to sustain their loss.

The device appears to be largely safe, with only about 4 percent of patients suffering a health problem because of the implant, the FDA's report on Maestro says.

However, the Maestro is unsafe during MRI scans and will have to be removed if a person needs an MRI, according to the FDA. The advisory panel has been asked to consider this as a potential risk in its evaluation.

Explore further: Weight-loss drug awaiting FDA approval combines antidepressant, addiction medications

More information: For more on obesity, visit the U.S. National Library of Medicine.

Related Stories

Weight-loss drug awaiting FDA approval combines antidepressant, addiction medications

June 11, 2014
On Wednesday, June 11, a new prescription weight-loss medication that combines a popular antidepressant with a medication for addiction will be reviewed by the Federal Drug Administration (FDA) for potential approval.

Weight loss surgery also safeguards obese people against cancer

June 4, 2014
Weight loss surgery might have more value than simply helping morbidly obese people to shed unhealthy extra pounds. It reduces their risk of cancer to rates almost similar to those of people of normal weight. This is the ...

Study exposes risk of nutritional deficiencies in obese teens

May 4, 2014
A new study exposes the risk of nutritional deficiencies in severely obese teens – both those who had weight loss surgery and those who did not.

Two JAMA Surgery studies examine bariatric surgery for type 2 diabetes treatment

June 4, 2014
Roux-en-Y gastric bypass surgery resulted in the greatest average weight and appears to be the best treatment for type 2 diabetes mellitus (T2DM) compared to gastric banding and lifestyle intervention in a clinical trial ...

Review finds weight-loss surgery safe and effective

December 18, 2013
(HealthDay)—A new review finds that weight-loss surgery helps very obese patients drop pounds and improve their overall health, even if there is some risk for complications.

New study paints grim health picture for obese teens

November 18, 2013
(HealthDay)—Severely obese teens are at increased risk for a host of serious health problems as adults, including asthma, kidney disease and sleep disorders, according to a new study.

Recommended for you

Study finds 90 percent of American men overfat

July 24, 2017
Does your waist measure more than half your height?

Are sugary drink interventions changing people's behaviour?

July 19, 2017
An evaluation of efforts designed to reduce how many sugary drinks we consume shows some success in changing younger people's habits but warns they cannot be the only way to cut consumption.

Young adult obesity: A neglected, yet essential focus to reverse the obesity epidemic

July 18, 2017
The overall burden of the U.S. obesity epidemic continues to require new thinking. Prevention of obesity in young adults, while largely ignored as a target for prevention and study, will be critical to reversing the epidemic, ...

Weight gain from early to middle adulthood may increase risk of major chronic diseases

July 18, 2017
Cumulative weight gain over the course of early and middle adulthood may increase health risks later in life, according to a new study led by researchers from Harvard T.H. Chan School of Public Health. They found that, compared ...

Study finds children carry implicit bias towards peers who are overweight

June 23, 2017
Even children as young as 9 years old can carry a prejudice against their peers who are overweight, according to a new study led by Duke Health researchers. They might not even realize they feel this way.

Mother's obesity boosts risk for major birth defects: study

June 15, 2017
Children of obese women are more likely to be afflicted by major birth defects, including malformations of the heart and genitals, according to a study published on Thursday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.